ETNB 250117 7.50C (ETNB250117C7500) Stock Options, News & Quotes

0.80
-0.14-14.89%

15min DelayClose Jan 2 16:00 ET

2.75High0.80Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Oct 15, 2024 07:51

NEWS

$89bio (ETNB.US)$
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
89bio (Nasdaq: ETNB) announced that new analyses from the Phase 2b ENLIVEN trial of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented at the 75th Annual AASLD The Liver Meeting® 2024. The presentations include four poster sessions focusing on:
Bio...

Meltyy

May 16, 2024 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Jaguar8

May 14, 2024 07:01

$89bio (ETNB.US)$
NEWS
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting ac...

Ryan fisher

Apr 2, 2024 16:06

$89bio (ETNB.US)$ 💀hope the strong buy suggestions promoter goto jail for fraud😭

Meltyy

Mar 21, 2024 01:57

According to Vantage market estimates for NASH could cross 100 Billion by 2030
NASH Basket- $Madrigal Pharmaceuticals (MDGL.US)$ $Viking Therapeutics (VKTX.US)$ $Akero Therapeutics (AKRO.US)$ $89bio (ETNB.US)$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics (VKTX.US)$ $Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$